Overview
Updated 14 Jul 2026
James Gulley, MD PHD FACP, is Senior Investigator and Acting Co-Director, Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute. The public record shows 985 publications with 28,235 citations (h-index 89), centered on Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, Prostate Cancer Treatment and Research. It also documents an investigator role on 28 registered clinical trials, industry payments reported by 2 companies.
- Most recent indexed publication: 2026 · Journal for immunotherapy of cancer
- Top research focus: Cancer Immunotherapy and Biomarkers
- 28 registered trials on ClinicalTrials.gov
- Open Payments reporting from 2 companies
Generated from the cited public record · current as of 14 Jul 2026. Every fact links its source below.
Indications focusfrom trials led + research topics
Research focusOpenAlex concept fingerprint
Drugs & moleculesacross trials, industry payments and publications
Works withtrial sponsors and companies reporting payments
Scholarshipindexed output and impact (OpenAlex)
View publications ↓Distinct works indexed by OpenAlex, matched via ORCID; 81 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 370.
Clinical & industrytrials, payments and federal funding
Federally funded research awards.
Clinical trials
Updated 14 Jul 2026
Listed as an investigator on 28 registered studies on ClinicalTrials.gov. The most recent:
- A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
Sponsor: National Cancer Institute (NCI)
InvestigatorPhase 1RecruitingNCT06066138 - A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Sponsor: Marengo Therapeutics, Inc.
InvestigatorPhase 1/PHASE2RecruitingNCT05592626 - N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer
Sponsor: National Cancer Institute (NCI)
InvestigatorPhase 2WithdrawnNCT05445882
Industry payments
Updated 14 Jul 2026
2 companies reported payments to CMS in program years 2024–2025. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year202511 payments
- Iovance Biotherapeutics, Inc.Program year20241 payment
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 14 Jul 2026
254 congress contributions (2004–2026) across AACR, ASCO, ASH, ASTRO, ESMO, SABCS per OpenAlex. The most recent:
- Abstract 5819: Anti-cancer immune effects of PT-112 monotherapy across two disease indications
AACR Annual Meeting
AACR2025Co-author - Abstract CT205: Updated clinical results, recommended phase 2 dose (RP2D) determination and translational study results for START-001: A phase 1/2 trial of invikafusp alfa, a first-in-class TCR b chain-targeted bispecific antibody in patients with anti-PD(L)1-resistant, antigen-rich solid tumors
AACR Annual Meeting
AACR2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Jul 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- PARP inhibition combined with a T-cell receptor β chain-directed antibody fusion molecule drives polyclonal antitumor immunity and tumor regression.
Journal for immunotherapy of cancer
2026 - Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer.
Journal for immunotherapy of cancer
2026
Most-cited worksby citation count (OpenAlex)
Contact
An office address from a public listing. This research profile has no federal registry record to draw from.
Office address
Building 10, Room 3-2551, Bethesda, MD 20892-1750
Network
Updated 14 Jul 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 14 Jul 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Educationdegrees and training on record
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →irp.nih.gov ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →irp.nih.gov ↗
- Medical Oncology Fellowship
National Cancer Institute
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →sto-online.org ↗
Editorial & leadership rolesjournal and society appointments
- Founding editor
Clinical/Translational Section, Journal for ImmunoTherapy of Cancer (JITC)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →irp.nih.gov ↗ - Member
Stand Up To Cancer (SU2C) Scientific Advisory Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →standuptocancer.org ↗
Awards & honorshonors on the public record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →irp.nih.gov ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →irp.nih.gov ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →irp.nih.gov ↗
Secondary affiliationsappointments beyond the home institution
- Director
Medical Oncology Service, Center for Cancer Research, NCI
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org ↗ - Attending physician
Genitourinary Malignancies Clinical Research Section, and Director of the Clinical Trials Group, Laboratory of Tumor Immunology and Biology, NCI
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →globaloncologyacademy.org ↗
Media & interviewspress, podcasts and appearances
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →facs.org ↗
- "James Gulley, MD, PhD: The Architecture of Evidence in Immuno-Oncology"
video interview/podcast
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Online presence
Updated 14 Jul 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accountspublic accounts run by this person
- Doximity
doximity.com/pub/james-gulley-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/nciprostatedoc
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - Other
ccr.cancer.gov/genitourinary-malignancies-branch/james-l-gulley
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ccr.cancer.gov ↗
Mentions by otherswhere others cite or feature them
- Other
blog.sitcancer.org/2021/12/meet-jitcs-new-deputy-editor-in-chief.html
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →blog.sitcancer.org ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - LinkedIn
LinkedIn: James Gulley MD PhD FACP - Clinical Director, National Cancer Institute (handle: nciprostatedoc)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Stephen Chanock, MD
National Cancer Institute
- 2,221
- publications
- 170
- h-index
Kevin Brown, MD
National Cancer Institute
- 463
- publications
- 87
- h-index
- 4
- trials